Product Information
SKYRIZI 360 MG/2.4 ML ON-BODY is a brand product labeled by AbbVie Inc., priced at $9679.4921 per ML under NDC 00074107001. Its NADAC has been published 97 times since Aug 21, 2024.
Manufacturer
AbbVie Inc.NDC
00074107001
Classification
Brand
Dosage Form
KIT
Route
INTRAVENOUS
Last Updated
1/2/2026
Approval Type
Biologic (BLA)
FDA Application
BLA761105On Market Since
6/16/2022
Price Statistics
The NADAC for SKYRIZI 360 MG/2.4 ML ON-BODY has been published 97 times since Aug 21, 2024, and over the history we have for it it has risen 13.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9679.4921 per ML |
|---|---|
| All-time high | $9679.4921 (Jun 24, 2026) |
| All-time low | $8515.5350 (Aug 21, 2024) |
| 52-week high | $9679.4921 |
| 52-week low | $9069.0448 |
| Median price | $9069.0448 |
| Average price | $9106.7691 |
| Largest weekly change | +6.5% (Jan 8, 2025) |
| Weeks tracked | 97 |
| Tracking since | Aug 21, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the Risankizumab-rzaa market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of SKYRIZI 360 MG/2.4 ML ON-BODY?
The current National Average Drug Acquisition Cost (NADAC) for SKYRIZI 360 MG/2.4 ML ON-BODY, manufactured by AbbVie Inc., is $9679.4921 per ML (NDC 00074107001), effective Jun 24, 2026.
How has the price of SKYRIZI 360 MG/2.4 ML ON-BODY changed over time?
Over the history we have for it, the NADAC for SKYRIZI 360 MG/2.4 ML ON-BODY has risen 13.7%. It has been tracked across 97 weekly CMS publications since Aug 21, 2024.
What are the highest and lowest recorded NADAC prices for SKYRIZI 360 MG/2.4 ML ON-BODY?
Since Aug 21, 2024, the NADAC for SKYRIZI 360 MG/2.4 ML ON-BODY has ranged from a low of $8515.5350 (Aug 21, 2024) to a high of $9679.4921 (Jun 24, 2026), with a median of $9069.0448 per ML.
Are there cheaper alternatives to SKYRIZI 360 MG/2.4 ML ON-BODY?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of SKYRIZI 360 MG/2.4 ML ON-BODY, so no direct lower-cost alternative is listed.
Who manufactures SKYRIZI 360 MG/2.4 ML ON-BODY?
SKYRIZI 360 MG/2.4 ML ON-BODY (NDC 00074107001) is labeled by AbbVie Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification